Company Overview of Ensemble Therapeutics Corporation
Ensemble Therapeutics Corporation develops and markets macrocycle therapeutics to the pharmaceutical industry. The company offers Ensemblins, a macrocycle drug to treat diseases by addressing drug targets, such as protein-protein interactions, phosphatases, and proteases; and Interleukin-17, a pro-inflammatory cytokine for the treatment of multiple inflammatory and autoimmune diseases, such as psoriasis, rheumatoid arthritis, Crohn’s, and intestinal bowel disease. The company’s products are used to treat cancer and autoimmune diseases, neurology, metabolic disease, infectious diseases, and diabetes. Ensemble Therapeutics Corporation has strategic alliance with Bristol-Myers Squibb; and Novar...
99 Erie Street
Cambridge, MA 02139-4535
Founded in 2002
Key Executives for Ensemble Therapeutics Corporation
Founding Scientist and Member of the Scientific Advisory Board
Senior Director of Finance & Administration
Senior Vice President of Biology
Senior Vice President of Corporate Development
Vice President of Screening & Biochemistry
Compensation as of Fiscal Year 2014.
Ensemble Therapeutics Corporation Key Developments
Ensemble Therapeutics Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Ensemble Therapeutics Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Ensemble Therapeutics and Novartis Announce Research and Development Collaboration Focused on Interleukin-17 Inhibitor Programme
Aug 7 13
Ensemble Therapeutics has announced a global strategic partnership with Novartis that will facilitate the development of Ensemble's lead investigational interleukin-17 (IL-17) cytokine inhibitor as well as a new initiative to discover novel small molecule candidates using Ensemble's proprietary drug discovery platform. Based on the agreement, Ensemble will receive an undisclosed upfront payment along with development and sales milestone payments. The firm will also be entitled to tiered royalties, if a successful candidate resulting from the collaboration is commercialized. The collaboration will further contribute to Novartis's inflammatory and autoimmune disorders portfolio, as the company can benefit from development of a first in class orally active small molecule IL-17 inhibitor that has been traditionally targeted with injectable protein therapeutics. According to Ensemble, the proprietary small molecule IL-17 inhibitor has comparable efficacy to existing biologic therapeutics targeting the cytokine in human clinical trials. Novartis will also have access to Ensemble's proprietary drug discovery chemistry-based technology that will try to develop and test various Ensemblins or synthetic macrocycles - small molecule candidates with protein surface binding properties. Macrocycles are difficult to synthesise on a large scale, but Ensemble has the capability of doing that in large numbers. Both companies stand to benefit, particularly in the large inflammatory and autoimmune market, if and when a candidate gains marketing approval.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries